PIK3C2A: A Promising Drug Target and Biomarker for Chronic Pain

Target Name: PIK3C2A

NCBI ID: G5286

PIK3C2A

PIK3C2A: A Promising Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain, along with its debilitating effects on physical and mental well-being, makes it difficult for patients to lead fulfilling lives. The regulation of pain signaling is a crucial aspect of pain management, and the atidylinositol-4-phosphate (PI) pathway is a key player in this process. PIK3C2A, a gene encoding the catalytic subunit type 2 alpha of the PI 3-kinase pathway, has been identified as a promising drug target and biomarker for chronic pain.

In this article, we will discuss the background of PIK3C2A, its function in the PI 3-kinase pathway, its potential as a drug target, and its role as a biomarker for chronic pain.

Background

PI 3-kinase is a protein that catalyzes the conversion of phosphatidylinositol (PI) to phosphatidylinositol 4-phosphate (PIP2) using ATP. The PI 3-kinase pathway is a critical regulatory pathway involved in various cellular processes, including cell signaling, cell survival , and cell growth. The PI 3-kinase pathway has been implicated in the regulation of pain signaling, and several studies have identified potential drug targets based on its involvement in pain.

PI 3-kinase is a protein that catalyzes the conversion of phosphatidylinositol (PI) to phosphatidylinositol 4-phosphate (PIP2) using ATP.

PI 3-kinase is a protein that catalyzes the conversion of phosphatidylinositol (PI) to phosphatidylinositol 4-phosphate (PIP2) using ATP. The PI 3-kinase pathway is a critical regulatory pathway involved in various cellular processes, including cell signaling, cell survival , and cell growth. The PI 3-kinase pathway has been implicated in the regulation of pain signaling, and several studies have identified potential drug targets based on its involvement in pain.

Expression and Functions of PIK3C2A

PI 3-kinase is a protein that is expressed in various tissues, including brain, heart, and pancreas. PIK3C2A is the catalytic subunit type 2 alpha of the PI 3-kinase pathway, and its function in this pathway is to catalyze the conversion of PI to PIP2 using ATP. PIK3C2A is a 120-kDa protein that consists of an N-terminal catalytic domain, a central catalytic domain, and a C-terminal hypervariable region (HVR).

PIK3C2A is a 120-kDa protein that consists of an N-terminal catalytic domain, a central catalytic domain, and a C-terminal hypervariable region (HVR).

PIK3C2A has been shown to play a crucial role in pain signaling. It is involved in the regulation of neurotransmitter release from pain interneur cells, which is a key step in the pain signaling pathway. Additionally, PIK3C2A has been shown to play a role in the modulation of pain perception, with decreased PIK3C2A levels leading to increased pain sensitivity.

PIK3C2A has also been shown to be involved in the regulation of platelet function, which is a critical aspect of pain signaling in the body. PIK3C2A has also been shown to regulate the aggregation and dissociation of platelets, which is important for the release of pain-releasing neurotransmitters.

PIK3C2A as a Drug Target

The identification of PIK3C2A as a potential drug target for chronic pain has significant implications for the treatment of chronic pain. By inhibiting

Protein Name: Phosphatidylinositol-4-phosphate 3-kinase Catalytic Subunit Type 2 Alpha

Functions: Generates phosphatidylinositol 3-phosphate (PtdIns3P) and phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) that act as second messengers. Has a role in several intracellular trafficking events. Functions in insulin signaling and secretion. Required for translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane and glucose uptake in response to insulin-mediated RHOQ activation. Regulates insulin secretion through two different mechanisms: involved in glucose-induced insulin secretion downstream of insulin receptor in a pathway that involves AKT1 activation and TBC1D4/AS160 phosphorylation, and participates in the late step of insulin granule exocytosis probably in insulin granule fusion. Synthesizes PtdIns3P in response to insulin signaling. Functions in clathrin-coated endocytic vesicle formation and distribution. Regulates dynamin-independent endocytosis, probably by recruiting EEA1 to internalizing vesicles. In neurosecretory cells synthesizes PtdIns3P on large dense core vesicles. Participates in calcium induced contraction of vascular smooth muscle by regulating myosin light chain (MLC) phosphorylation through a mechanism involving Rho kinase-dependent phosphorylation of the MLCP-regulatory subunit MYPT1. May play a role in the EGF signaling cascade. May be involved in mitosis and UV-induced damage response. Required for maintenance of normal renal structure and function by supporting normal podocyte function. Involved in the regulation of ciliogenesis and trafficking of ciliary components (PubMed:31034465)

The "PIK3C2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PIK3C2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets